Epiomic Epidemiology Series: Autoimmune Haemolytic Anemia Forecast in 8 Major Markets 2016-2026 - PowerPoint PPT Presentation

About This Presentation
Title:

Epiomic Epidemiology Series: Autoimmune Haemolytic Anemia Forecast in 8 Major Markets 2016-2026

Description:

This report provides the current incident population for AIHA across 8 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil and Japan) split by gender and 5-year age cohort. – PowerPoint PPT presentation

Number of Views:32

less

Transcript and Presenter's Notes

Title: Epiomic Epidemiology Series: Autoimmune Haemolytic Anemia Forecast in 8 Major Markets 2016-2026


1
Epiomic Epidemiology Series Autoimmune
Haemolytic Anemia Forecast in 8 Major Markets
2016-2026
  • Market Research Report

Telephone 1(503)894-6022 Mail at
Sales_at_researchbeam.com
2
Report Overview
  • Epiomic Epidemiology Series Forecast Report on
    Autoimmune Haemolytic Anaemia (AIHA) in 8 Major
    Markets
  • Autoimmune haemolytic anaemia (AIHA) is an immune
    disorder caused by auto-antibodies against
    unmodified autologous red blood cells and can
    range in presentation from a mild illness to a
    rapidly fatal severe condition.
  • This report provides the current incident
    population for AIHA across 8 Major Markets (USA,
    France, Germany, Italy, Spain, UK, Brazil and
    Japan) split by gender and 5-year age cohort.
    Along with the current incidence, the report also
    contains a disease overview of the risk factors,
    disease diagnosis and prognosis along with
    specific variations by geography and ethnicity.
  • Providing a value-added level of insight from the
    analysis team at, several of the main symptoms
    and co-morbidities of AIHAs have been quantified
    and presented alongside the overall incidence
    figures. These sub-populations within the main
    disease are also included at a country level
    across the 10-year forecast snapshot.

3
Main symptoms and co-morbidities for AIHA include
  • Lymphoproliferative conditions
  • CLL
  • HL
  • NHL
  • Myeloproliferative conditions
  • Multiple myeloma
  • Myelofibrosis
  • MGUS
  • Autoimmune conditions
  • RA
  • SLE
  • Polyarteritis nodosa
  • Infections
  • Pneumonia Tuberculosis
  • Syphilis
  • Epstein-Barr
  • Chronic active hepatitis
  • Mononucleosis

4
Reason to buy
  • This report is built using data and information
    sourced from the proprietary Epiomic patient
    segmentation database. To generate accurate
    patient population estimates, the Epiomic
    database utilizes a combination of several world
    class sources that deliver the most up to date
    information from patient registries, clinical
    trials and epidemiology studies. All of the
    sources used to generate the data and analysis
    have been identified in the report.
  • Able to quantify patient populations in global
    AIHAs market to target the development of future
    products, pricing strategies and launch plans.
  • Gain further insight into the incidence of the
    subdivided types of AIHA and identify patient
    segments with high potential.
  • Delivery of more accurate information for
    clinical trials in study sizing and realistic
    patient recruitment for various countries.
  • Provide a level of understanding on the impact
    from specific co-morbid conditions on AIHAs
    incident population.
  • Identify sub-populations within AIHA which
    require treatment.
  • Gain an understanding of the specific markets
    that have the largest number of AIHA patients.

5
Table Of Content
  • List of Tables and Figures Introduction
    Cause of the Disease Risk Factors
    Prevention Diagnosis of the Disease Variation
    by Geography/Ethnicity Disease Prognosis
    Clinical Course Clinical Management of AIHAo
    Transfusion therapy in AIHA Key Co-morbid
    Conditions/Features Associated with the Disease
    Methodology for Quantification of Patient
    Numbers Top-Line Incidence for AIHA  Subtypes
    of AIHA patientso Warm AIHA patientso Cold AIHA
    patientso Mixed-type AIHA patients Market
    Forecast for AIHAo 1st Line Treatment Options
    within Warm Mixed-type AIHAo 2nd Line
    Treatment Options within Warm Mixed-type AIHAo
    1st Line Treatment Options within Cold AIHAo 2nd
    Line Treatment Options within Cold AIHAo
    Requirement for Blood Transfusions within AIHA
    Methodology for Forecast Figures Abbreviations
    used in the report  Other Black Swan Analysis
    Publications Black Swan Analysis Online
    Patient-Based Databases Patient-Based
    Offering Online Pricing Data and Platforms
    References Appendix 

6
Find More Details
  • http//www.researchbeam.com/epiomic-epidemiology-s
    eries-autoimmune-haemolytic-anemia-forecast-in-8-m
    ajor-2016-2026-market/enquire-about-report

Stay With Us
5933 NE Win Sivers Drive,205, Portland, OR
97220United States
TELEPHONE 1 (800) 910-6452 DIRECT 1 (503)
894-6022E-MAIL sales_at_researchbeam.com
Write a Comment
User Comments (0)
About PowerShow.com